Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 20/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12635080 | 1.00 | CTSK (0.63) | CTSK | |
| SCHEMBL418758 | 1.00 | CTSK (0.63) | CTSK | |
| SCHEMBL3285479 | 0.90 | CTSK (0.78) | CTSK | |
| SCHEMBL3623912 | 0.90 | CTSK (0.78) | CTSK | |
| SCHEMBL8576225 | 0.90 | CTSK (0.78) | CTSK | |
| SCHEMBL31471965 | 0.89 | CTSK (0.71) | CTSK | |
| SCHEMBL22433834 | 0.86 | CTSK (0.63) | CTSK | |
| SCHEMBL1802737 | 0.86 | CTSK (0.66) | CTSK | |
| SCHEMBL12538274 | 0.86 | CTSK (0.66) | CTSK | |
| SCHEMBL374867 | 0.86 | CTSK (0.66) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014083582-A2 | NOVEL PROCESS FOR THE PREPARATION OF (1S,3AR,6AS)-2-[(2S)-2-({(2S)-2-CYCLOHEXYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]ACETYL}AMINO)-3,3-DIMETHYLBUTANOYL]-N-[(3S)-1-(CYCLOPROPYLAMINO)-1,2-DIOXOHEXAN-3-YL]-3,3A,4,5,6,6A-HEXAHYDRO-1H-CYCLOPENTA[C] PYRROLE-1-CARBOXAMIDE AND ITS INTERMEDIATES | MSN LABORATORIES LIMITED (IN) | 2014-06-05 | — | — | WO | claimed |
| WO-2024119026-A1 | BORON-CONTAINING CYCLIC EMISSIVE COMPOUNDS AND COLOR CONVERSION FILM CONTAINING THE SAME | NITTO DENKO CORPORATION (JP) | 2024-06-06 | — | — | WO | disclosed |
| CN-116969889-B | Preparation method of phenanthridine or chiral phenanthridine compound | 瑞博(杭州)医药科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-116969889-A | Preparation method of phenanthridine or chiral phenanthridine compound | 瑞博(杭州)医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-2268285-B1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2014083582-A2 | NOVEL PROCESS FOR THE PREPARATION OF (1S,3AR,6AS)-2-[(2S)-2-({(2S)-2-CYCLOHEXYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]ACETYL}AMINO)-3,3-DIMETHYLBUTANOYL]-N-[(3S)-1-(CYCLOPROPYLAMINO)-1,2-DIOXOHEXAN-3-YL]-3,3A,4,5,6,6A-HEXAHYDRO-1H-CYCLOPENTA[C] PYRROLE-1-CARBOXAMIDE AND ITS INTERMEDIATES | MSN LABORATORIES LIMITED (IN) | 2014-06-05 | — | — | WO | disclosed |
| US-8211897-B2 | Inhibitors of cathepsin B | VIROBAY, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| EP-2237793-A1 | INHIBITORS OF CATHEPSIN B | Virobay, Inc. (US) | 2010-10-13 | — | — | EP | disclosed |
| WO-2007005838-A2 | HCV INHIBITORS | VIROBAY, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20050059606-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON CORPORATION (US) | 2005-03-17 | — | — | US | disclosed |
| US-6800434-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1301528-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20030036501-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON PHARMACEUTICALS LLC | 2003-02-20 | — | — | US | disclosed |
| WO-2002008256-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
| EP-1171127-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATIVES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | Targacept, Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000062767-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | TARGACEPT, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-0639585-A1 | Elastase inhibitor | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | CTSK 243/4885 |
| US-20050059606-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | VIP, HPN, TMPRSS15 | CTSK 244/4885 |
| US-20030036501-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | VIP, HPN, TMPRSS15 | CTSK 244/4885 |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CTSK 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.